Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sensitive multicolor indicators for monitoring norepinephrine in vivo. | Nat Methods | 2023 | 37474807 | PubTator, text mining | PubMed |
| BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation - design, synthesis and biological evaluation. | Biomed Pharmacother | 2023 | 37473684 | PubTator, text mining | PubMed |
| TNF superfamily control of tissue remodeling and fibrosis. | Front Immunol | 2023 | 37465675 | PubTator, text mining | PubMed |
| Prognostic and immunological significance of an M1 macrophage-related gene signature in osteosarcoma. | Front Immunol | 2023 | 37465666 | PubTator, text mining | PubMed |
Correction: Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors. | J Immunother Cancer | 2023 | 37463792 | PubTator, text mining | PubMed |
| Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors. | J Immunother Cancer | 2023 | 37463789 | PubTator, text mining | PubMed |
| A novel disulfidptosis-related immune checkpoint genes signature: forecasting the prognosis of hepatocellular carcinoma. | J Cancer Res Clin Oncol | 2023 | 37462769 | PubTator, text mining | PubMed |
| Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma. | JAMA Netw Open | 2023 | 37459093 | PubTator, text mining | PubMed |
| Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer. | Front Immunol | 2023 | 37457699 | PubTator, text mining | PubMed |
| Immunomodulatory Therapy for Giant Cell Myocarditis: A Narrative Review. | Cureus | 2023 | 37456487 | PubTator, text mining | PubMed |
| Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy. | Cancers (Basel) | 2023 | 37444586 | PubTator, text mining | PubMed |
| Identification of N7-methylguanosine-related lncRNAs for the risk stratification of hepatocellular carcinoma. | J Gastrointest Oncol | 2023 | 37435203 | PubTator, text mining | PubMed |
| Single-cell sequencing and bulk RNA data reveal the tumor microenvironment infiltration characteristics of disulfidptosis related genes in breast cancer. | J Cancer Res Clin Oncol | 2023 | 37428249 | PubTator, text mining | PubMed |
| How molecular advances may improve the diagnosis and management of PTCL patients. | Front Oncol | 2023 | 37427095 | PubTator, text mining | PubMed |
| Comprehensively analysis of immunophenotyping signature in triple-negative breast cancer patients based on machine learning. | Front Pharmacol | 2023 | 37426809 | PubTator, text mining | PubMed |
| Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity. | Front Cell Infect Microbiol | 2023 | 37424786 | PubTator, text mining | PubMed |
| Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy. | iScience | 2023 | 37416452 | PubTator, text mining | PubMed |
| Transcriptome analysis of human macrophages upon chikungunya virus (CHIKV) infection reveals regulation of distinct signaling and metabolic pathways during the early and late stages of infection. | Heliyon | 2023 | 37408916 | PubTator, text mining | PubMed |
| Construction and validation of a novel cuproptosis-mitochondrion prognostic model related with tumor immunity in osteosarcoma. | PLoS One | 2023 | 37405988 | PubTator, text mining | PubMed |
| Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas. | Biomark Res | 2023 | 37403120 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=25